StemlineTherapeutics Inc. (NASDAQ:STML) has been given an average rating of “Buy” by the seven research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $31.33.
A number of research firms recently issued reports on STML. BidaskClub upgraded StemlineTherapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, March 13th. ValuEngine downgraded StemlineTherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of StemlineTherapeutics in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded StemlineTherapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 15th.
Shares of StemlineTherapeutics stock traded down $0.10 during trading hours on Thursday, hitting $15.10. The company’s stock had a trading volume of 212,667 shares, compared to its average volume of 432,785. StemlineTherapeutics has a 12 month low of $7.30 and a 12 month high of $18.75. The company has a market capitalization of $456.17, a P/E ratio of -5.14 and a beta of 0.07.
StemlineTherapeutics (NASDAQ:STML) last announced its quarterly earnings results on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.26). StemlineTherapeutics had a negative return on equity of 94.70% and a negative net margin of 4,689.63%. equities research analysts expect that StemlineTherapeutics will post -2.62 EPS for the current fiscal year.
In other StemlineTherapeutics news, insider David Gionco sold 4,250 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Kenneth Hoberman sold 14,040 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $13.93, for a total value of $195,577.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 156,418 shares of company stock valued at $2,628,131. 16.70% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of STML. State Street Corp grew its stake in StemlineTherapeutics by 11.3% in the second quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock valued at $3,179,000 after purchasing an additional 35,116 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in StemlineTherapeutics by 40.1% in the second quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,522 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in StemlineTherapeutics by 82.0% in the third quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock valued at $2,434,000 after purchasing an additional 98,775 shares in the last quarter. Lyon Street Capital LLC grew its stake in StemlineTherapeutics by 331.1% in the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after purchasing an additional 415,867 shares in the last quarter. Finally, Cowen Inc. bought a new position in StemlineTherapeutics in the third quarter valued at approximately $420,000. Hedge funds and other institutional investors own 49.87% of the company’s stock.
TRADEMARK VIOLATION WARNING: “StemlineTherapeutics Inc. (STML) Receives $31.33 Consensus PT from Analysts” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/stemlinetherapeutics-inc-stml-receives-31-33-consensus-pt-from-analysts.html.
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Receive News & Ratings for StemlineTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemlineTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.